Patients with opioid use disorder (OUD) who exhibited minimal to mild withdrawal at baseline experienced positive outcomes with use of an injectable 7‐day formulation of buprenorphine, a nonrandomized trial has found. The study sample of 100 adults reported few serious adverse events and a high degree of satisfaction with the extended‐release formulation of buprenorphine.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: